CorMedix/CRMD

$3.55

0.57%
-
1D1W1MYTD1YMAX

About CorMedix

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on developing its product DefenCath, which is an antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic emodialysis. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL intended for the reduction of catheter-related infections and thrombosis in patients requiring central venous catheters CVCs in clinical settings, such as hemodialysis, total parenteral nutrition and oncology. In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.

Ticker

CRMD

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Joseph Todisco

Employees

40

Headquarters

Berkeley heights, United States

CorMedix Metrics

BasicAdvanced
$181.43M
Market cap
-
P/E ratio
-$0.86
EPS
1.83
Beta
-
Dividend rate

What the Analysts think about CorMedix

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 4 analysts.
273.24% upside
High $19.00
Low $10.00
$3.55
Current price
$13.25
Average price target

CorMedix Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-9.7M
-13.39%
Profit margin
0%
-

CorMedix Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 18.17%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.20
-$0.24
-$0.25
-$0.17
-
Expected
-$0.19
-$0.20
-$0.24
-$0.21
-$0.20
Surprise
6.95%
20%
3.59%
-18.17%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell CorMedix stock

Buy or sell CorMedix stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing